Outcomes Steadily Improve for Multiple Myeloma Treated With ASCT

MONDAY, Feb. 24, 2020 -- For patients with multiple myeloma (MM) treated with autologous stem cell transplantation (ASCT), long-term outcomes have improved steadily, according to a study published in the Jan. 28 issue of Blood Advances. Katherine K....
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

Abstract AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. High-dose intravenous melphalan and autologous stem cell transplantation was developed for the treatment of AL amyloidosis in the early 1990s and was prompted by its success in myeloma. This application has evolved significantly over the past three decades. This review provides a comprehensive assessment of eligibility criteria, stem cell collection, and mobilization strategies and regimens, risk-adapted melphalan dosing, role for induction and consolidation therapies as well as long-term outcome with resp...
Source: Acta Haematologica - Category: Hematology Authors: Tags: Acta Haematol Source Type: research
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
PML should be considered in patients with neurological symptoms following MM and in those who are immunosuppressed. Symptoms are diverse and often rapidly progressing. Prompt referral and early involvement of the multidisciplinary team are crucial. AbstractPML should be considered in patients with neurological symptoms following MM and in those who are immunosuppressed. Symptoms are diverse and often rapidly progressing. Prompt referral and early involvement of the multidisciplinary team are crucial.
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research
Multiple myeloma (MM) is a plasma cell neoplasm, which currently affects approximately 100,000 people in the US. Although the introduction of novel agent therapies for MM has led to a significant improvement in outcomes, autologous stem cell transplant (ASCT) remains the standard of care in the upfront management for this disease based on randomized controlled trial data demonstrating prolonged time in remission compared to novel agents alone [1].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: Brief Article Source Type: research
High-dose chemotherapy, followed by an autologous stem cell transplantation (ASCT) has served as a successful treatment for newly diagnosed multiple myeloma patients for more than 30 years [1,2]. Tandem ASCT was introduced in the 1990 ’s and showed promising results compared to conventional chemotherapy in terms of prolonged event-free and overall survival (EFS and OS, respectively) [3–5]. Since then, several studies compared single and tandem ASCT and showed partially contradictory results. Some authors suggested a superiori ty of the tandem compared to single ASCT in terms of better EFS, prolonged relapse-fre...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
Publication date: Available online 12 March 2020Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Hao Meng Yip, Kwee Yong, Dunnya De-Silva, Neil Rabin
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
Authors: Morè S, Corvatta L, Maracci L, Costantini B, Olivieri A, Offidani M Abstract Introduction: Multiple Myeloma (MM) is a very heterogeneous clonal plasma cell hematological malignancy for which new therapies and transplantation effectively improve Progression-free survival (PFS) and overall survival (OS). Maintenance seems to have made a significant contribution in achieving these advances, whereas the real role of consolidation is still controversial. Despite lenalidomide having been approved as maintenance therapy after autologous stem cell transplantation (ASCT), the optimal maintenance agent, drug ...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Multiple myeloma (MM), a bone marrow–resident hematological malignancy of plasma cells, has remained largely incurable despite dramatic improvements in patient outcomes in the era of myeloma-targeted and immunomodulatory agents. It has recently become clear that T cells from MM patients are able to recognize and eliminate myeloma, although this is subverted in the majority of patients who eventually succumb to progressive disease. T cell exhaustion and a suppressive bone marrow microenvironment have been implicated in disease progression, and once these are established, immunotherapy appears largely ineffective. Auto...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Authors: Mei AH, Tung K, Han J, Perumal D, Laganà A, Keats J, Auclair D, Chari A, Jagannath S, Parekh S, Cho HJ Abstract The type I Melanoma Antigen Gene (MAGE) A3 is a functional target associated with survival and proliferation in multiple myeloma (MM). To investigate the mechanisms of these oncogenic functions, we performed gene expression profiling (GEP) of p53 wild-type human myeloma cell lines (HMCL) after MAGE-A knockdown, which identified a set of 201 differentially expressed genes (DEG) associated with apoptosis, DNA repair, and cell cycle regulation. MAGE knockdown increased protein levels of pro-a...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Myeloma | Pharmaceuticals | Stem Cell Therapy | Stem Cells | Study | Transplants